Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
about
Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approachTransfusion thresholds and other strategies for guiding allogeneic red blood cell transfusionTransfusion thresholds and other strategies for guiding allogeneic red blood cell transfusionVertical transmission of the hepatitis C virus: Current knowledge and issuesEstimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study.Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers.Do expert assessments converge? An exploratory case study of evaluating and managing a blood supply risk.Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysisRisk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.Occult hepatitis B virus infection and blood transfusionGuidance on the use of increased infectious risk donors for organ transplantation.Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity.Reducing the risk of hepatitis B virus transfusion-transmitted infectionWhat every physician should know about transfusion reactions.Blood donors' positivity for transfusion-transmissible infections: the Serbian Military Medical Academy experience.Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors.Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.Undisclosed human immunodeficiency virus risk factors identified through a computer-based questionnaire program among blood donors in Brazil.Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentReduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood componentsAccuracy of physician reporting in routine public health surveillance for hepatitis C virus infection.Assessment and treatment of preoperative anemia: Continuing Professional Development.Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing.Human T-lymphotropic virus and transfusion safety: does one size fit all?A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors.Selection strategies for newly registered blood donors in European countries.Evaluation of an isolation program of hepatitis C virus infected hemodialysis patients in some hemodialysis centers in egypt.Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors.Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations.NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results.Trends in transfusion-transmissible infections among Australian blood donors from 2005 to 2010.Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008.Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa.
P2860
Q21089975-DE6C9DDF-5B30-482C-A2FB-CEB87DA01B95Q24200170-5BFC8DCC-6F46-4736-8D32-B1B9CD90F38EQ24234502-3A29CF67-2EDB-4073-89C5-3179A84773C3Q24652942-89A61416-0F0D-4282-A06E-36477E89790AQ30394281-376050FE-AE53-4687-AFFD-95E1C67BD2B8Q33873316-1DD96311-3D85-4A49-8C98-0615551C5F7AQ34001785-40ECC256-0BC7-4020-B7AD-B290B99CECFEQ34346207-5FA2CD39-6708-418F-BF52-4E5C4A801F1EQ35032348-E79CB985-99D5-43B9-A22F-C90C49121E2AQ35032861-18A26B49-2936-451D-9149-E5AE6E56B6A8Q35237335-2D97D9E3-61A2-43E7-AFD9-999D7F0C0DA1Q35295449-654C194D-746C-49D1-B677-A0622AE7EE81Q35664869-A3CF1B47-32F4-4E16-AFAA-48CAECC0780EQ35683881-1C33E42C-49ED-4FAE-AA50-C62836A1159EQ35878583-3DE17447-29B7-4635-A8B4-1F3EC250DE23Q36220045-BEAFD60E-B3AE-4A21-87EF-E094CD181C19Q36652701-738DD959-6038-4092-8264-818756B4262FQ36903922-3A9B2F3F-7C4C-47B6-A1D6-631EDCB5387BQ37004488-B501401C-A0CD-4E63-8461-970EAE4C6C7AQ37013124-AC9E0AB0-5693-435B-AB27-5021418775AEQ37100669-DD522DD6-02FC-4DDA-BC6F-E6305F4A5815Q37209101-6ACEC426-6E53-4440-A6EF-09F7F55E6D5FQ37391715-FAFF5967-6159-4E5D-8B31-C583EF386274Q37864226-31179F65-EB82-41EB-8F18-8D5DD7CC8E24Q37997349-D85208E6-A63A-4405-937D-C79ED541EF96Q38403039-E57AB498-C864-4200-AEF9-01BC4665D3FDQ38590004-F2A7DD37-652A-45A1-9C97-DBDC4576286AQ39137413-835F81DC-4B5A-4532-9FBE-379295DAC70CQ39306032-994061FC-3ABB-4AD8-BAC9-B131B82DF6A1Q40305015-26FDAE4A-61D4-4BA9-B4D4-413386BB0668Q42245717-EB956D1A-1CA1-4474-85CD-1BC31A8D6399Q42283514-438340E6-BEA2-4CF7-835D-0AED8C4D35BCQ42588946-6C6190CB-1DB6-4EDD-BA02-791EB957884AQ42977201-46D28AEC-9375-4905-B6FD-91F3A413173AQ42981169-4BD1C123-4269-4CC0-938D-AFFF7361C165Q42993391-DC2F8CC4-37FD-4CE7-910C-AB3E152BB834Q43047121-80D6CB6D-94F1-49E3-AD5F-3EA7020E7540Q43406238-6CB9ACC8-FCB4-4316-926E-6C7C6C6BCDDEQ43851125-37F22279-93DD-4214-B8EA-DFB2945A0C78Q43870929-FD126C9C-538C-44B9-B81E-5AB6C820C83C
P2860
Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Current incidence and estimate ...... de to Canadian Blood Services.
@en
Current incidence and estimate ...... de to Canadian Blood Services.
@nl
type
label
Current incidence and estimate ...... de to Canadian Blood Services.
@en
Current incidence and estimate ...... de to Canadian Blood Services.
@nl
prefLabel
Current incidence and estimate ...... de to Canadian Blood Services.
@en
Current incidence and estimate ...... de to Canadian Blood Services.
@nl
P2093
P2860
P1433
P1476
Current incidence and estimate ...... de to Canadian Blood Services.
@en
P2093
Eleftherios C Vamvakas
Qi-Long Yi
Sheila F O'Brien
Steven H Kleinman
Vito Scalia
P2860
P304
P356
10.1111/J.1537-2995.2007.01108.X
P577
2007-02-01T00:00:00Z